Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial
Titel:
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial
Auteur:
Berger, Jeffrey S. Roe, Matthew T. Gibson, C. Michael Kilaru, Rakhi Green, Cynthia L. Melton, Laura Blankenship, James D. Metzger, D. Christopher Granger, Christopher B. Gretler, Daniel D. Grines, Cindy L. Huber, Kurt Zeymer, Uwe Buszman, Pawel Harrington, Robert A. Armstrong, Paul W.